Formulary Watch |

Formulary Watch covers formularies, pharmacy benefit management companies, drug approvals, and other matters related to medications, their prices and insurance coverage.

Editorial Contact: Denise Myshko: dmyshko@mjhlifesciences.com

All News

FDA Approves Ekterly, First Oral Treatment for Hereditary Angioedema
FDA Approves Ekterly, First Oral Treatment for Hereditary Angioedema
FDA Approves Ekterly, First Oral Treatment for Hereditary Angioedema
July 7, 2025
Orsini will be the specialty pharmacy partner for Ekterly.
Lynozyfic Shows 70% Response Rate in Heavily Pre-Treated Multiple Myeloma Patients, FDA Grants Accelerated Approval
Lynozyfic Shows 70% Response Rate in Heavily Pre-Treated Multiple Myeloma Patients, FDA Grants Accelerated Approval
Lynozyfic Shows 70% Response Rate in Heavily Pre-Treated Multiple Myeloma Patients, FDA Grants Accelerated Approval
July 2, 2025
According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy multiple myeloma cells.
Tada Images-stock@adobe.com
Optum Rx Eliminates Reauthorization on an Additional 60 Drugs
Optum Rx Eliminates Reauthorization on an Additional 60 Drugs
June 30, 2025
Optum Rx officials said they now have eliminated reauthorization requirements for more than 140 chronic disease medications.
Prime Study Finds Low Long-Term Adherence to GLP-1 Obesity Drugs
Prime Study Finds Low Long-Term Adherence to GLP-1 Obesity Drugs
Prime Study Finds Low Long-Term Adherence to GLP-1 Obesity Drugs
June 26, 2025
A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in adherence in 2024, suggesting there is an evolving understanding of obesity treatment.
AliFuat-stock@adobe.com
Plans Agree to Prior Auth Reform. Physicians and Business Groups Want Measurable Results
Plans Agree to Prior Auth Reform. Physicians and Business Groups Want Measurable Results
June 24, 2025
More than 50 insurers have pledged to streamline and simplify the prior authorization process through six new commitments.
Patrick Bay Damsted-stock@adobe.com
Novo Nordisk Terminates Collaboration with Hims & Hers
Novo Nordisk Terminates Collaboration with Hims & Hers
June 23, 2025
The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded semaglutide products. Novo Nordisk said that Hims & Hers continues to offer these compounded drugs.
FDA Approves Dupixent as First Targeted Treatment for Bullous Pemphigoid in Adults
FDA Approves Dupixent as First Targeted Treatment for Bullous Pemphigoid in Adults
FDA Approves Dupixent as First Targeted Treatment for Bullous Pemphigoid in Adults
June 20, 2025
This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and have limited treatment options.
FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma
FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma
FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma
June 19, 2025
This is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) and the second indication for Monjuvi.
FDA Approves Hereditary Angioedema Therapy, Andembry
FDA Approves Hereditary Angioedema Therapy, Andembry
FDA Approves Hereditary Angioedema Therapy, Andembry
June 18, 2025
CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.
NDA Resubmitted for Investigational Dry Eye Therapy, Reproxalap
NDA Resubmitted for Investigational Dry Eye Therapy, Reproxalap
NDA Resubmitted for Investigational Dry Eye Therapy, Reproxalap
June 17, 2025
Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new data from an additional FDA-requested trial.
leesle-stock.adobe.com
Sandoz Launches Biosimilars of Xgeva/Prolia
Sandoz Launches Biosimilars of Xgeva/Prolia
June 17, 2025
Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and osteoporosis.
Timon-stock.adobe.com
Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients
Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients
June 16, 2025
A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys.
Biosimilar Uptake Has Been Slow but This is Changing
Biosimilar Uptake Has Been Slow but This is Changing
Biosimilar Uptake Has Been Slow but This is Changing
June 13, 2025
In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, talks about the factors that are impacting the biosimilar market.
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13, 2025
The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
FDA Approves Ibtrozi For Adults With ROS1+ NSCLC
FDA Approves Ibtrozi For Adults With ROS1+ NSCLC
FDA Approves Ibtrozi For Adults With ROS1+ NSCLC
June 12, 2025
Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, according to the results of a news release.
FDA Approves Enflonsia To Protect Infants During Their First RSV Season
FDA Approves Enflonsia To Protect Infants During Their First RSV Season
FDA Approves Enflonsia To Protect Infants During Their First RSV Season
June 12, 2025
Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.
Blue Shield of California Breaks Up Pharmacy Benefit; Other Payers Considering the Same Approach
Blue Shield of California Breaks Up Pharmacy Benefit; Other Payers Considering the Same Approach
Blue Shield of California Breaks Up Pharmacy Benefit; Other Payers Considering the Same Approach
June 10, 2025
A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy benefits as a way for better control.
Requiring Humira Biosimilars Results in Huge Savings for Navitus Clients
Requiring Humira Biosimilars Results in Huge Savings for Navitus Clients
Requiring Humira Biosimilars Results in Huge Savings for Navitus Clients
June 10, 2025
Switching to Humira biosimilars saved Navitus clients more than $315 million in upfront costs in 2024 and resulted in a 60% reduction in net costs per claim.
ckybe-stock.adobe.com
Transparency for PBMs. Can It Become Something More than Just a Buzzword?
Transparency for PBMs. Can It Become Something More than Just a Buzzword?
June 6, 2025
The pharmacy benefit manager (PBM) industry is under pressure to shift to models that avoid conflicts of interest and misaligned incentives.
FDA Approved Bayer’s Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
FDA Approved Bayer’s Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
FDA Approved Bayer’s Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
June 5, 2025
The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation therapy (ADT), reduced the risk of radiographic progression or death by 46% compared to ADT with placebo.
yavdat-stock.adobe.com
States Become More Aggressive with PBM Reform
States Become More Aggressive with PBM Reform
May 30, 2025
State efforts are aiming to bring more disclosure and transparency to PBM practices, mandating certain pharmacy reimbursement levels, requiring 100% pass-through rebates, and prohibiting spread pricing.
utah51-stock.adobe.com
Milliman: Healthcare Costs for Americans Have Almost Tripled in 20 Years
Milliman: Healthcare Costs for Americans Have Almost Tripled in 20 Years
May 29, 2025
Pharmacy costs and outpatient facility care generate 69% of the cost increase for 2025, according to Milliman’s recent Medical Index.
Chief Pharmacy Officer Jason R. Smith on the Challenges Health Systems Face
Chief Pharmacy Officer Jason R. Smith on the Challenges Health Systems Face
Chief Pharmacy Officer Jason R. Smith on the Challenges Health Systems Face
May 28, 2025
Jason R. Smith, Pharm.D., appointed as chief pharmacy officer in February 2025 for the University of Rochester Medical Center, talks about building a stronger workforce, managing drug shortages and keeping up with changes in regulations because of the new administration.
FDA Approves Nucala as Maintenance Therapy for COPD
FDA Approves Nucala as Maintenance Therapy for COPD
FDA Approves Nucala as Maintenance Therapy for COPD
May 23, 2025
Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.
© 2025 MJH Life Sciences

All rights reserved.